<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03840148</url>
  </required_header>
  <id_info>
    <org_study_id>VNRX-5133-201</org_study_id>
    <secondary_id>2018-001451-13</secondary_id>
    <nct_id>NCT03840148</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections</brief_title>
  <official_title>A Phase 3, Randomized, Double-blind, Active Controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VenatoRx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VenatoRx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of cefepime/VNRX-5133 compared with meropenem
      in both eradication of bacteria and in symptomatic response in patients with cUTIs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2019</start_date>
  <completion_date type="Anticipated">February 27, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of microbiological eradication and symptomatic clinical success in the microbiological intent-to-treat (microITT) population at test of cure (TOC)</measure>
    <time_frame>Days 19-23</time_frame>
    <description>Microbiologic eradication is defined as demonstration that any gram negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to &lt;10^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiological and symptomatic success at test of cure (TOC)</measure>
    <time_frame>Days 19-23</time_frame>
    <description>The proportion of patients with both microbiological success and symptomatic clinical success at TOC in the extended microITT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and microbiological success at end of treatment (EOT) and last follow-up (LFU)</measure>
    <time_frame>24 hours after last IV dose, Days 28-35</time_frame>
    <description>The proportion of patients with both microbiological success and symptomatic clinical success at EOT and LFU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-patient microbiological success at EOT, TOC and LFU</measure>
    <time_frame>Within 24 hours of last IV dose, Days 19-23, Days 28-35</time_frame>
    <description>The proportion of patients with per-patient microbiological success at EOT, TOC and LFU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with symptomatic clinical success at EOT, TOC and LFU</measure>
    <time_frame>Within 24 hours of last IV dose, Days 19-23, Days 28-35</time_frame>
    <description>The proportion of patients with symptomatic clinical success at EOT, TOC and LFU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator opinion of clinical success at TOC</measure>
    <time_frame>Days 19-23</time_frame>
    <description>The proportion of patients with clinical success based on investigator opinion at TOC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen microbiological success at EOT, TOC and LFU</measure>
    <time_frame>Within 24 hours of last IV dose, Days 19-23, Days 28-35</time_frame>
    <description>The proportion of patients with per-pathogen microbiological success at EOT, TOC and LFU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological and clinical success in cefepime-resistant pathogens at EOT, TOC and LFU</measure>
    <time_frame>Within 24 hours of last IV dose, Days 19-23, Days 28-35</time_frame>
    <description>The proportion of patients with both microbiological success and symptomatic clinical success among those with cefepime-resistant pathogens at EOT, TOC and LFU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-patient microbiological success among those with cefepime-resistant pathogens at EOT, TOC and LFU</measure>
    <time_frame>Within 24 hours of last IV dose, Days 19-23, Days 28-35</time_frame>
    <description>The proportion of patients with per-patient microbiological success among those with cefepime-resistant pathogens at EOT, TOC and LFU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen microbiological success among those with cefepime-resistant pathogens at EOT, TOC and LFU</measure>
    <time_frame>Within 24 hours of last IV dose, Days 19-23, Days 28-35</time_frame>
    <description>The proportion of patients with per-pathogen microbiological success among those with cefepime-resistant pathogens at EOT, TOC and LFU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic clinical success among those with cefepime-resistant pathogens at EOT, TOC and LFU cefepime-resistant pathogens</measure>
    <time_frame>Within 24 hours of last IV dose, Days 19-23, Days 28-35</time_frame>
    <description>The proportion of patients with symptomatic clinical success among those with cefepime-resistant pathogens at EOT, TOC and LFU.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Days 35</time_frame>
    <description>Percent of participants experiencing adverse events.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with serious adverse events</measure>
    <time_frame>Days 35</time_frame>
    <description>Percent of participants experiencing serious adverse events.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">582</enrollment>
  <condition>Urinary Tract Infections</condition>
  <condition>Acute Pyelonephritis</condition>
  <arm_group>
    <arm_group_label>Cefepime/VNRX-5133 (taniborbactam)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meropenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meropenem will be administered q8h IV over 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefepime/VNRX-5133 (taniborbactam)</intervention_name>
    <description>Patients will also receive meropenem placebo administered via IV over 30 minutes.</description>
    <arm_group_label>Cefepime/VNRX-5133 (taniborbactam)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>Patients will also receive cefepime/VNRX-5133 placebo administered via IV over a 2-hour period.</description>
    <arm_group_label>Meropenem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male and female

          -  Documented diagnosis of pyuria

          -  Documented diagnosis of cUTI or Acute Pyelonephritis (AP)

        Exclusion Criteria:

          -  Receipt of effective antibacterial drug therapy for cUTI for more than 24 hours during
             the previous 72 hours prior to randomization

          -  A urine culture result is resistant to meropenem or a gram negative pathogen is not
             identified or more than 2 microorganisms are isolated or a confirmed fungal UTI is
             identified

          -  Required use of nonstudy systemic bacterial therapy

          -  Suspected or confirmed prostatitis or urinary tract symptoms attributable to sexually
             transmitted disease

          -  Patients with perinephric or renal abscess

          -  Patients with renal transplantation or receiving hemodialysis or peritoneal dialysis

          -  Abnormal labs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Venatorx</last_name>
    <phone>610-644-8935</phone>
    <email>venatorxclinical@venatorx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site 184003</name>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <zip>90620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 184002</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 184001</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 184009</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 184007</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 110009</name>
      <address>
        <city>Gabrovo</city>
        <zip>5300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 110002</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 110007</name>
      <address>
        <city>Plovdiv</city>
        <zip>4003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 110003</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 110010</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 110004</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 110005</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 110008</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 110001</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 156022</name>
      <address>
        <city>Baotou</city>
        <zip>014010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 156001</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 156002</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 156006</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 156030</name>
      <address>
        <city>Fujian</city>
        <zip>362202</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 156014</name>
      <address>
        <city>Guangdong</city>
        <zip>515041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 156027</name>
      <address>
        <city>Guangdong</city>
        <zip>518035</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 156016</name>
      <address>
        <city>Shijiazhuang</city>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 119103</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 119101</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 134802</name>
      <address>
        <city>Budapest</city>
        <zip>1087</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 134801</name>
      <address>
        <city>Budapest</city>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 134803</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 134804</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 142803</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV-5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 142804</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 142801</name>
      <address>
        <city>Riga</city>
        <zip>LV-1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 148402</name>
      <address>
        <city>Colima</city>
        <zip>28018</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>China</country>
    <country>Croatia</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 6, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bacterial Infections</keyword>
  <keyword>Cefepime</keyword>
  <keyword>Meropenem</keyword>
  <keyword>Complicated Urinary Tract Infections</keyword>
  <keyword>Anti-Infective Agents</keyword>
  <keyword>β-Lactamase Inhibitors</keyword>
  <keyword>VNRX-5133 (taniborbactam)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Pyelonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Cefepime</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

